Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Entacapone differs from tolcapone in the following
respect/respects:
A. It is shorter acting
B. It acts only by inhibiting peripheral
metabolism of levodopa
C. It is not hepatotoxic
D. All of the above are correct
by

1 Answer

Answer :

D. All of the above are correct
by

Related questions

The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of dopamine methylation in the brain C. Inhibition of oxidative deamination of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Description : The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of ... of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Last Answer : A. Inhibition of levodopa methylation in the liver

The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Description : The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Last Answer : A. It acts by inhibiting degradation of dopamine in the brain

In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of action C. It activates dopamine D2 receptors, with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Last Answer : D. It does not produce behavioral/psychiatric side effects

Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Description : Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Last Answer : C. It does not have antiandrogenic action

Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Description : Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Last Answer : D. Both 'B' and 'C' are correct

Which of the following drugs acts by inhibiting an enzyme in the body: A. Atropine B. Allopurinol C. Levodopa D. Metoclopramide

Description : Which of the following drugs acts by inhibiting an enzyme in the body: A. Atropine B. Allopurinol C. Levodopa D. Metoclopramide

Last Answer : B. Allopurinol

The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the ‘on-off ’ effect in levodopa treated advanced parkinsonian patients C. It retards the progression of Parkinson's disease D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Description : The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the on-off ' effect in levodopa treated advanced parkinsonian ... D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Last Answer : . At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Carbimazole differs from propylthiouracil in that: A. It is dose to dose less potent B. It has a shorter plasma half life C. It does not produce an active metabolite D. It does not inhibit peripheral conversion of thyroxine to triiodothyronine

Description : Carbimazole differs from propylthiouracil in that: A. It is dose to dose less potent B. It has a shorter plasma half life C. It does not produce an active metabolite D. It does not inhibit peripheral conversion of thyroxine to triiodothyronine

Last Answer : D. It does not inhibit peripheral conversion of thyroxine to triiodothyronine

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Description : Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Last Answer : A. It is less likely to cause rebound hypertension on sudden discontinuation

Compared with distribution for consumer product marketing mixes, the distribution ingredient in business to business marketing differs in all of the following respects EXCEPT:A)types of channels used tend to be shorter. B)other kinds of middlemen are available. C)transportation policies differ. D)value is added to the product. E)direct channels are used widely.

Description : Compared with distribution for consumer product marketing mixes, the distribution ingredient in business to business marketing differs in all of the following respects EXCEPT:A)types of channels used tend to be ... policies differ. D)value is added to the product. E)direct channels are used widely.

Last Answer : D)value is added to the product.

Fluphenazine differs from chlorpromazine in the following respects except: A. It has higher antipsychotic efficacy B. It is less sedative C. It is less likely to precipitate seizures in epileptics D. It causes more prominent extrapyramidal side effect

Description : Fluphenazine differs from chlorpromazine in the following respects except: A. It has higher antipsychotic efficacy B. It is less sedative C. It is less likely to precipitate seizures in epileptics D. It causes more prominent extrapyramidal side effect

Last Answer : A. It has higher antipsychotic efficacy

Which of the following drugs acts by inhibiting an enzyme in the body: A. Atropine B. Allopurinol C. Levodopa D. Metoclopramide

Description : Which of the following drugs acts by inhibiting an enzyme in the body: A. Atropine B. Allopurinol C. Levodopa D. Metoclopramide

Last Answer : B. Allopurinol

(B) decreasing peripheral metabolism of levodopa (C) decreasing metabolism of levodopa in the CNS (D) decreasing clearance of levodopa from the CNS

Description : (B) decreasing peripheral metabolism of levodopa (C) decreasing metabolism of levodopa in the CNS (D) decreasing clearance of levodopa from the CNS

Last Answer : (B) decreasing peripheral metabolism of levodopa

Though bromocriptine acts directly on dopamine receptors, it is used in parkinsonism only as a supplement to levodopa because: A. It has low efficacy B. It produces marked dyskinesias C. Used alone, its effective doses produce intolerable side effects D. Its therapeutic effect takes long time to develop

Description : Though bromocriptine acts directly on dopamine receptors, it is used in parkinsonism only as a supplement to levodopa because: A. It has low efficacy B. It produces marked dyskinesias C. ... its effective doses produce intolerable side effects D. Its therapeutic effect takes long time to develop

Last Answer : C. Used alone, its effective doses produce intolerable side effect

Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Description : Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Last Answer : D. Inhibiting peripheral glucose utilization

Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Description : Adrenaline raises blood glucose level by the following actions except: A. Inducing hepatic glycogenolysis B. Inhibiting insulin secretion from pancreatic β cells C. Augmenting glucagon secretion from pancreatic α cells D. Inhibiting peripheral glucose utilization

Last Answer : D. Inhibiting peripheral glucose utilization

What is true of Quinupristin-Dalfopristin: A. It is a synergistic combination of two similar antibiotics B. It acts by inhibiting bacterial protein synthesis C. It is active against most resistant coccal infections D. All of the above are correct

Description : What is true of Quinupristin-Dalfopristin: A. It is a synergistic combination of two similar antibiotics B. It acts by inhibiting bacterial protein synthesis C. It is active against most resistant coccal infections D. All of the above are correct

Last Answer : D. All of the above are correct

Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Description : Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Last Answer : C. It is less liable to cause abrupt first dose hypotension

riiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action

Description : riiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action

Last Answer : B. It has a shorter plasma half life

17.2 Triiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action (

Description : 17.2 Triiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action (

Last Answer : B. It has a shorter plasma half life

Choose the correct statement about drotaverine: A. It is a smooth muscle antispasmodic acting by non-anticholinergic mechanisms B. It is a papaverine congener used in peripheral vascular diseases C. It is a synthetic atropine substitute used to control diarrhoea D. It is a M1/M3 selective antagonist used for spastic constipation

Description : Choose the correct statement about drotaverine: A. It is a smooth muscle antispasmodic acting by non-anticholinergic mechanisms B. It is a papaverine congener used in peripheral vascular diseases C. It ... used to control diarrhoea D. It is a M1/M3 selective antagonist used for spastic constipation

Last Answer : A. It is a smooth muscle antispasmodic acting by non-anticholinergic mechanisms

Piperacillin differs from carbenicillin in the following respect(s): A. It is more active against Pseudomonas aeruginosa B. It is active against Klebsiella as well C. It is acid resistant D. Both ‘A’ and ‘B’ are correct

Description : Piperacillin differs from carbenicillin in the following respect(s): A. It is more active against Pseudomonas aeruginosa B. It is active against Klebsiella as well C. It is acid resistant D. Both ‘A’ and ‘B’ are correct

Last Answer : D. Both ‘A’ and ‘B’ are correct

The 'new formula' WHO-ORS differs from the older 'standard formula' WHO-ORS in the following respect(s): A. It has lower Na+ ion and glucose concentration B. It has higher K+ ion concentration C. It has no basic salt D. Both 'B' and 'C' are correct

Description : The 'new formula' WHO-ORS differs from the older 'standard formula' WHO-ORS in the following respect(s): A. It has lower Na+ ion and glucose concentration B. It has higher K+ ion concentration C. It has no basic salt D. Both 'B' and 'C' are correct

Last Answer : A. It has lower Na+ ion and glucose concentration

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

Morphine analgesia differs from that produced by aspirin in the following respect(s): A. It has a higher ceiling B. It covers both perception as well as psychic processing of the pain C. Visceral and ischaemic pain is relieved better than somatic inflammatory pain D. All of the above are correct

Description : Morphine analgesia differs from that produced by aspirin in the following respect(s): A. It has a higher ceiling B. It covers both perception as well as psychic processing of the pain C. Visceral and ischaemic pain is relieved better than somatic inflammatory pain D. All of the above are correct

Last Answer : D. All of the above are correct

Triamterene differs from spironolactone in that: A. It has greater natriuretic action B. Its K+ retaining action is not dependent on presence of aldosterone C. It acts from the luminal membrane side of the distal tubular cells D. Both ‘B’ and ‘C’ are correct

Description : Triamterene differs from spironolactone in that: A. It has greater natriuretic action B. Its K+ retaining action is not dependent on presence of aldosterone C. It acts from the luminal membrane side of the distal tubular cells D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

The following cytotoxic drug acts by inhibiting depolymerization of tubulin and thus producing abnormal arrays of microtubules: A. Paclitaxel B. Vinblastine C. Etoposide D. Mitoxantrone (p. 774) 60.9 C 60.10 B 60.11 D 60.12 A Ai

Description : The following cytotoxic drug acts by inhibiting depolymerization of tubulin and thus producing abnormal arrays of microtubules: A. Paclitaxel B. Vinblastine C. Etoposide D. Mitoxantrone (p. 774) 60.9 C 60.10 B 60.11 D 60.12 A Ai

Last Answer : A. Paclitaxel

Select the drug that acts by inhibiting HIV protease enzyme: A. Zalcitabine B. Efavirenz C. Stavudine D. Nelfinavi

Description : Select the drug that acts by inhibiting HIV protease enzyme: A. Zalcitabine B. Efavirenz C. Stavudine D. Nelfinavi

Last Answer : D. Nelfinavir

Select the drug that is fungicidal and acts by inhibiting fungal squalene epoxidase enzyme: A. Ketoconazole B. Terbinafine C. Tolnaftate D. Hamycin

Description : Select the drug that is fungicidal and acts by inhibiting fungal squalene epoxidase enzyme: A. Ketoconazole B. Terbinafine C. Tolnaftate D. Hamycin

Last Answer : B. Terbinafine

The following is true of vancomycin except: A. It is a bactericidal antibiotic active primarily against gram positive bacteria B. It acts by inhibiting bacterial protein synthesis C. It is an alternative to penicillin for enterococcal endocarditis D. It can cause deafness as a dose related toxicity

Description : The following is true of vancomycin except: A. It is a bactericidal antibiotic active primarily against gram positive bacteria B. It acts by inhibiting bacterial protein synthesis C. It is an alternative to penicillin for enterococcal endocarditis D. It can cause deafness as a dose related toxicity

Last Answer : B. It acts by inhibiting bacterial protein synthesis

Furosemide acts by inhibiting the following in the renal tubular cell: A. Na+-K+-2Cl– cotransporter B. Na+-Cl– symporter C. Na+-H+ antiporter D. Na+ K+ ATPase

Description : Furosemide acts by inhibiting the following in the renal tubular cell: A. Na+-K+-2Cl– cotransporter B. Na+-Cl– symporter C. Na+-H+ antiporter D. Na+ K+ ATPase

Last Answer : A. Na+-K+-2Cl– cotransporter

Features of µ (Mu) opioid receptor include the following except: A. Acts by inhibiting cAMP formation B. Mediates miotic action C. Mediates low ceiling respiratory depression D. Mediates high ceiling supraspinal analgesia

Description : Features of µ (Mu) opioid receptor include the following except: A. Acts by inhibiting cAMP formation B. Mediates miotic action C. Mediates low ceiling respiratory depression D. Mediates high ceiling supraspinal analgesia

Last Answer : C. Mediates low ceiling respiratory depression

The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Description : The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Last Answer : C. Selegiline

Carbimazole acts by inhibiting: A. Iodide trapping B. Oxidation of iodide C. Proteolysis of thyroglobulin D. Synthesis of thyroglobulin protein

Description : Carbimazole acts by inhibiting: A. Iodide trapping B. Oxidation of iodide C. Proteolysis of thyroglobulin D. Synthesis of thyroglobulin protein

Last Answer : B. Oxidation of iodide

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Which of the following antitubercular drugs is not hepatotoxic: A. Isoniazid B. Rifampicin C. Pyrazinamide D. Ethambutol

Description : Which of the following antitubercular drugs is not hepatotoxic: A. Isoniazid B. Rifampicin C. Pyrazinamide D. Ethambutol

Last Answer : D. Ethambutol

The following is not true of the cytochrome P450 isoenzyme CYP2D6: A. It generates the hepatotoxic metabolite N-acetyl benzoquinone immine from paracetamol B. It is involved in demethylation of codeine into morphine C. Its altered form is responsible for poor capacity to hydroxylate many drugs including metoprolol D. It is inhibited by quinidine

Description : The following is not true of the cytochrome P450 isoenzyme CYP2D6: A. It generates the hepatotoxic metabolite N-acetyl benzoquinone immine from paracetamol B. It is involved in demethylation of ... for poor capacity to hydroxylate many drugs including metoprolol D. It is inhibited by quinidine

Last Answer : A. It generates the hepatotoxic metabolite N-acetyl benzoquinone immine from paracetamol

The following is a reversible and selective MAO-A inhibitor: A. Bupropion B. Entacapone C. Moclobemide D. Selegiline

Description : The following is a reversible and selective MAO-A inhibitor: A. Bupropion B. Entacapone C. Moclobemide D. Selegiline

Last Answer : C. Moclobemide

Select the drug that reversibly inhibits the enzyme COMT and is useful as an adjuvant medication in advanced parkinson's disease: A. Pramipexole B. Entacapone C. Pergolide D. Piribedil

Description : Select the drug that reversibly inhibits the enzyme COMT and is useful as an adjuvant medication in advanced parkinson's disease: A. Pramipexole B. Entacapone C. Pergolide D. Piribedil

Last Answer : B. Entacapone

The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Description : The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Last Answer : A. α-methyl-p-tyrosine

Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Description : Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Last Answer : D. All of the above

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

Morphine produces analgesia by acting at: A. Peripheral pain receptors B. A spinal site C. Supraspinal sites D. Both spinal and supraspinal sites

Description : Morphine produces analgesia by acting at: A. Peripheral pain receptors B. A spinal site C. Supraspinal sites D. Both spinal and supraspinal sites

Last Answer : D. Both spinal and supraspinal sites

Vincristine differs from vinblastine in the following respect(s): A. Its prominent adverse effect is neuropathy B. It frequently produces alopecia C. It does not significantly depress bone marrow D. All of the above

Description : Vincristine differs from vinblastine in the following respect(s): A. Its prominent adverse effect is neuropathy B. It frequently produces alopecia C. It does not significantly depress bone marrow D. All of the above

Last Answer : D. All of the above

As per WHO guidelines, treatment of failure or relapse (category II) patients of smear positive pulmonary tuberculosis differs from that of new cases in the following respect(s): A. All 5 first line antitubercular drugs are given in the initial intensive phase B. Duration of intensive phase is increased to 5 months C. Three drugs (HRE) are given in the continuation phase instead of two (HR) D. Both 'A' and 'C'

Description : As per WHO guidelines, treatment of failure or relapse (category II) patients of smear positive pulmonary tuberculosis differs from that of new cases in the following respect(s): A. All 5 first line antitubercular drugs ... are given in the continuation phase instead of two (HR) D. Both 'A' and 'C'

Last Answer : D. Both 'A' and 'C'

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Last Answer : D. Both ‘B’ and ‘C’ are correct

Enalapril differs from captopril in the following features except: A. It is dose to dose more potent B. Its oral absorption is not affected by food in stomach C. It acts more rapidly D. It has longer duration of action

Description : Enalapril differs from captopril in the following features except: A. It is dose to dose more potent B. Its oral absorption is not affected by food in stomach C. It acts more rapidly D. It has longer duration of action

Last Answer : D. Lisinopri

Choose the correct statement about nateglinide: A. It is a long acting oral hypoglycaemic drug B. Taken just before a meal, it limits postprandial hyperglycaemia in type 2 diabetes mellitus C. It lowers blood glucose in both type 1 and type 2 diabetes mellitus D. It acts by opening K+ channels in myocytes and adipocytes

Description : Choose the correct statement about nateglinide: A. It is a long acting oral hypoglycaemic drug B. Taken just before a meal, it limits postprandial hyperglycaemia in type 2 diabetes mellitus C. It lowers ... 1 and type 2 diabetes mellitus D. It acts by opening K+ channels in myocytes and adipocytes

Last Answer : B. Taken just before a meal, it limits postprandial hyperglycaemia in type 2 diabetes mellitus